Opportunities

Chemistry/Immunology Reagents/Analyzer

Special Notice from Defense Health Agency (dha), solicitation HT941027N0014. Responses due Dec 3, 2026. NAICS 325413, No Set aside used. Listed on SAM.gov.

Solicitation
HT941027N0014
Notice type
Special Notice
Department
Dept of Defense
Agency
Defense Health Agency (dha)
Office
Defense Health Agency HCD West
Posted
Nov 19, 2026
Responses due
Dec 3, 2026
Product/service code
6550
Set-aside
No Set aside used
Listed on
SAM.gov

Description

Notice of Intent to Sole Source HT941027N0014 THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division � San Diego (HCD-SD), Echo Branch intends to award a firm fixed price five (5)-Year Purchase order RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government�s needs, to: ORTHO CLINICAL DIAGNOSTICS SINGAPORE PTE LTD, KOREA BRANCH 366 HANGANG-DAERO YONGSAN-GU, SEOUL, 04323 SOUTH KOREA UEI: JNSJRDQQH2J6 CAGE: 767DF The North American Industry Classification System (NAICS) code for this requirement is 325413 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,250 (in number of employees). The Product Service Code (PSC) is 6550 � Invitro Diagnostics Substances Reagents The objective of this sole source award is to procure Chemistry/Immunology Reagents with Analyzer for Brian D. Allgood Army Community Hospital, South Korea for the Department of Pathology. The contractor-furnished chemistry and immunology analyzers shall be capable of providing complete chemistry and immunochemistry testing. The entire analyzer system shall be serviced and supplied through a single Contractor awarded the contract, including all parts, equipment, and supplies not manufactured, provided, or serviced directly by the Contractor. The system shall provide redundancy to ensure continuous operations. Each analyzer shall have the capacity to perform both chemistry and immunology assays. The Contractor shall provide the system, training, supplies, reagents, unscheduled maintenance, and preventive maintenance. All equipment displays and supporting literature shall be in English. The Contractor shall include delivery, installation, all calibrators and standards, reagents and reagent packs, and quality-control materials necessary to perform the specified assays. The Contractor shall also perform initial method validations in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The Contractor shall remove the analyzers upon contract termination. Rationale Justifying: Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation, is the sole manufacturer capable of providing clinical chemistry and integrated chemistry/immunoassay analyzers that meet the Government�s test-volume requirements without requiring a facility water supply. The Defense Health Agency requires analyzers that use 100 percent waterless, dry-slide technology. These sites cannot receive reagent-grade water into the facility for safe, quality laboratory testing and are not approved by the state to discharge biohazardous waste into any drain. This technology is unique to QuidelOrtho�s VITROS� line of analyzers and is essential to meeting the agency�s operational and mission requirements for the following reasons: Infrastructure Independence: VITROS dry-slide technology eliminates the need for water, plumbing, and drains. This is a critical advantage in military healthcare environments, where logistical footprints must be minimized. It ensures operational continuity and significantly reduces infrastructure dependencies. Enhanced Quality and Reliability: The system uses disposable tips for each sample, eliminating the risk of sample-to-sample carryover and reagent-to-reagent contamination that can occur in traditional wet-chemistry systems. This supports the accuracy and reliability of test results for patient care, particularly for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, accurate first-run results for high-sensitivity troponin to triage potential heart attacks; procalcitonin and lactic acid to diagnose life-threatening sepsis; and potassium levels to treat sudden acute renal or metabolic failure. In these life-threatening situations, a false or contaminated initial result can delay critical medical intervention. The dry-slide technology�s elimination of sample carryover helps ensure that providers can rely on the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides calibration stability of up to six months for most assays. This extended calibration interval substantially reduces the time and labor associated with daily calibration and quality-control procedures while also reducing reagent waste.systems. This ensures the highest accuracy and reliability of test results for patient care, which is absolutely critical for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, flawless first-time results for high sensitivity troponin to triage imminent heart attacks, procalcitonin and lactic acid to diagnose life-threatening sepsis, and potassium levels to treat sudden acute renal or metabolic failure. In these life-or-death scenarios, a false or contaminated first read delays vital medical interventions; the dry-slide technology's elimination of sample carryover ensures providers can trust the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides up to a six-month calibration stability for most assays. This extended frequency drastically reduces the time and labor spent on daily calibration and quality control procedures while decreasing reagent waste. …

Loading the opportunity